1.Tamoxifen and the Risk of Parkinson's Disease in Female Patients with Breast Cancer in Asian People: A Nationwide Population-Based Study.
Chien Tai HONG ; Lung CHAN ; Chaur Jong HU ; Chien Min LIN ; Chien Yeh HSU ; Ming Chin LIN
Journal of Breast Cancer 2017;20(4):356-360
PURPOSE: Whether tamoxifen affects the risk of neurodegenerative disease is controversial. This nationwide population-based study investigated the risk of Parkinson's disease (PD) associated with tamoxifen treatment in female patients with breast cancer using Taiwan's National Health Insurance Research Database. METHODS: A total of 5,185 and 5,592 female patients with breast cancer who did and did not, respectively, receive tamoxifen treatment between 2000 and 2009 were included in the study. Patients who subsequently developed PD were identified. A Cox proportional hazards model was used to compare the risk of PD between the aforementioned groups. RESULTS: Tamoxifen did not significantly increase the crude rate of developing PD in female patients with breast cancer (tamoxifen group, 16/5,169; non-tamoxifen group, 11/5,581; p=0.246). Tamoxifen did not significantly increase the adjusted hazard ratio (aHR) for subsequently developing PD (aHR, 1.310; 95% confidence interval [CI], 0.605–2.837; p=0.494). However, tamoxifen significantly increased the risk of PD among patients followed up for more than 6 years (aHR, 2.435; 95% CI, 1.008–5.882; p=0.048). CONCLUSION: Tamoxifen treatment may increase the risk of PD in Taiwanese female patients with breast cancer more than 6 years after the initiation of treatment.
Asian Continental Ancestry Group*
;
Breast Neoplasms*
;
Breast*
;
Female*
;
Humans
;
National Health Programs
;
Neurodegenerative Diseases
;
Parkinson Disease*
;
Proportional Hazards Models
;
Tamoxifen*
2.Efficacy and safety of herbal medicine yun-cai tea in the treatment of hyperlipidemia: A double-blind placebo-controlled clinical trial.
Chien-Ying LEE ; Min-Chien YU ; Chun-Che LIN ; Ming-Yung LEE ; James Cheng-Chung WEI ; Hung-Che SHIH
Chinese journal of integrative medicine 2015;21(8):587-593
OBJECTIVEAnimal studies have demonstrated a lipid-modulating effect of yun-cai tea. However, little is known about the lipid-lowering effect in humans.The aim of this study was to evaluate the lipid lowering effects and safety of yun-cai tea in patients with elevated lipid levels in a human clinical trial.
METHODSThis was a 12-week, randomly assigned, parallel-group, double-blind, and placebo-controlled pilot clinical study. Sixty primary hyperlipidemia patients were included and randomly assigned to the yun-cai tea group (30 patients) and the placebo group (30 patients), for 8 weeks of treatment and 4 weeks of follow-up. The primary endpoint was changes in plasma low-density lipoprotein-cholesterol (LDL-C) at 8 weeks. The secondary endpoints included total cholesterol (TC) and triglycerides (TG).
RESULTSOur results revealed no statistically signifificant differences in LDL-C and TC between the two groups. Despite the lack of a statistically signifificant difference in the level of TG between the two groups, a declining trend was noted. A signifificant reduction of TG was observed in the yun-cai tea group at week 8, compared to baseline (P=0.048). The incidence of stomach discomfort, gastroesophageal reflfl ux, diarrhea, and constipation was slightly higher in the yun-cai tea group. No other signifificant adverse events were found.
CONCLUSIONIt is unlikely that yun-cai tea used had a blood lipid reduction effect. Further larger scale clinical trials with a longer duration and larger dose are necessary.
Adult ; Double-Blind Method ; Drugs, Chinese Herbal ; therapeutic use ; Female ; Herbal Medicine ; Humans ; Hyperlipidemias ; drug therapy ; Hypolipidemic Agents ; therapeutic use ; Male ; Middle Aged ; Placebos
3.Ancient migration routes of Austronesian-speaking populations in oceanic Southeast Asia and Melanesia might mimic the spread of nasopharyngeal carcinoma.
Jean TREJAUT ; Chien-Liang LEE ; Ju-Chen YEN ; Jun-Hun LOO ; Marie LIN
Chinese Journal of Cancer 2011;30(2):96-105
Mitochondrial DNA (mtDNA) and non-recombining Y chromosome (NRY) are inherited uni-parentally from mother to daughter or from father to son respectively. Their polymorphism has initially been studied throughout populations of the world to demonstrate the "Out of Africa" hypothesis. Here, to correlate the distribution of nasopharyngeal carcinoma (NPC) in different populations of insular Asia, we analyze the mtDNA information (lineages) obtained from genotyping of the hyper variable region (HVS I & II) among 1400 individuals from island Southeast Asia (ISEA), Taiwan and Fujian and supplemented with the analysis of relevant coding region polymorphisms. Lineages that best represented a clade (a branch of the genetic tree) in the phylogeny were further analyzed using complete genomic mtDNA sequencing. Finally, these complete mtDNA sequences were used to construct a most parsimonious tree which now constitutes the most up-to-date mtDNA dataset available on ISEA and Taiwan. This analysis has exposed new insights of the evolutionary history of insular Asia and has strong implications in assessing possible correlations with linguistic, archaeology, demography and the NPC distribution in populations within these regions. To obtain a more objective and balanced genetic point of view, slowly evolving biallelic Y single nucleotide polymorphism (Y-SNP) was also analyzed. As in the first step above, the technique was first applied to determine affinities (macro analysis) between populations of insular Asia. Secondly, sixteen Y short tandem repeats (Y-STR) were used as they allow deeper insight (micro analysis) into the relationship between individuals of a same region. Together, mtDNA and NRY allowed a better definition of the relational, demographic, cultural and genetic components that constitute the make up of the present day peoples of ISEA. Outstanding findings were obtained on the routes of migration that occurred along with the spread of NPC during the settlement of insular Asia. The results of this analysis will be discussed using a conceptual approach.
Asia, Southeastern
;
epidemiology
;
Asian Continental Ancestry Group
;
genetics
;
Base Sequence
;
Chromosomes, Human, Y
;
genetics
;
DNA, Mitochondrial
;
genetics
;
Emigration and Immigration
;
Genetics, Population
;
Haplotypes
;
genetics
;
Humans
;
Melanesia
;
epidemiology
;
Microsatellite Repeats
;
Nasopharyngeal Neoplasms
;
epidemiology
;
genetics
;
Oceanic Ancestry Group
;
genetics
;
Phylogeny
;
Polymorphism, Single Nucleotide
;
Taiwan
;
epidemiology
4.The development of Taiwan Fracture Liaison Service network
Lo Yu CHANG ; Keh Sung TSAI ; Jen Kuei PENG ; Chung Hwan CHEN ; Gau Tyan LIN ; Chin Hsueh LIN ; Shih Te TU ; I Chieh MAO ; Yih Lan GAU ; Hsusan Chih LIU ; Chi Chien NIU ; Min Hong HSIEH ; Jui Teng CHIEN ; Wei Chieh HUNG ; Rong Sen YANG ; Chih Hsing WU ; Ding Cheng CHAN
Osteoporosis and Sarcopenia 2018;4(2):45-50
Osteoporosis and its associated fragility fractures are becoming a severe burden in the healthcare system globally. In the Asian-Pacific (AP) region, the rapidly increasing in aging population is the main reason accounting for the burden. Moreover, the paucity of quality care for osteoporosis continues to be an ongoing challenge. The Fracture Liaison Service (FLS) is a program promoted by International Osteoporosis Foundation (IOF) with a goal to improve quality of postfracture care and prevention of secondary fractures. In this review article, we would like to introduce the Taiwan FLS network. The first 2 programs were initiated in 2014 at the National Taiwan University Hospital and its affiliated Bei-Hu branch. Since then, the Taiwan FLS program has continued to grow exponentially. Through FLS workshops promoted by the Taiwanese Osteoporosis Association (TOA), program mentors have been able to share their valuable knowledge and clinical experience in order to promote establishments of additional programs. With 22 FLS sites including 11 successfully accredited on the best practice map, Taiwan remains as one of the highest FLS coverage countries in the AP region, and was also granted the IOF Best Secondary Fracture Prevention Promotion award in 2017. Despite challenges faced by the TOA, we strive to promote more FLS sites in Taiwan with a main goal of ameliorating further health burden in managing osteoporotic patients.
Aging
;
Awards and Prizes
;
Delivery of Health Care
;
Education
;
Financing, Organized
;
Humans
;
Mentors
;
Osteoporosis
;
Practice Guidelines as Topic
;
Taiwan
5.Malignant transformation of ovarian mature cystic teratoma into squamous cell carcinoma: a Taiwanese Gynecologic Oncology Group (TGOG) study.
An Jen CHIANG ; Min Yu CHEN ; Chia Sui WENG ; Hao LIN ; Chien Hsing LU ; Peng Hui WANG ; Yu Fang HUANG ; Ying Cheng CHIANG ; Mu Hsien YU ; Chih Long CHANG
Journal of Gynecologic Oncology 2017;28(5):e69-
OBJECTIVE: The malignant transformation (MT) of ovarian mature cystic teratoma (MCT) to squamous cell carcinoma (SCC) is very rare. This study analyzed cases from multiple medical centers in Taiwan to investigate the clinicopathologic characteristics, treatment, and prognostic factors of this disease and reviewed related literature. METHODS: Pathological reports of 16,001 patients with primary ovarian cancer who were treated at Taiwan medical centers from 1990 to 2011 were reviewed. In total, 52 patients with MT of MCT to SCC were identified. RESULTS: Among all ovarian MCTs, the incidence of MT to SCC is 0.2%. The median age of patients was 52 years (range, 29–89 years), and the mean tumor size was 10.5 cm (range, 1–40 cm). We analyzed the patients in our study and those in the literature and determined that early identification and complete surgical resection of the tumor are essential for long-term survival. In addition, adjuvant chemotherapy or concurrent chemoradiotherapy can be used to treat this malignancy. Old age, large tumor size (≥15.0 cm), and solid components in MCTs are suitable indicators predicting the risk of MT of MCT to SCC. CONCLUSION: Similar to general epithelial ovarian cancers, the early detection of MT of MCT to SCC is critical to long-term survival. Therefore, older patients with a large tumor or those with a tumor containing a solid component in a clinically diagnosed MCT should be evaluated to exclude potential MT to SCC.
Carcinoma, Squamous Cell*
;
Cell Transformation, Neoplastic
;
Chemoradiotherapy
;
Chemotherapy, Adjuvant
;
Epithelial Cells*
;
Humans
;
Incidence
;
Ovarian Neoplasms
;
Taiwan
;
Teratoma*
6.Metallic Stent Placement in Hemodialysis Graft Patients after Insufficient Balloon Dilation.
Huei Lung LIANG ; Huay Ben PAN ; Yih Huie LIN ; Chiung Yu CHEN ; Hsiao Min CHUNG ; Tung Ho WU ; Kang Ju CHOU ; Pin Hong LAI ; Chien Fang YANG
Korean Journal of Radiology 2006;7(2):118-124
OBJECTIVE: We wanted to report our experience of metallic stent placement after insufficient balloon dilation in graft hemodialysis patients. MATERIALS AND METHODS: Twenty-three patients (13 loop grafts in the forearm and 10 straight grafts in the upper arm) underwent metallic stent placement due to insufficient flow after urokinase thrombolysis and balloon dilation. The indications for metallic stent deployment included 1) recoil and/or kinked venous stenosis in 21 patients (venous anastomosis: 17 patients, peripheral outflow vein: four patients); and 2) major vascular rupture in two patients. Metallic stents 8-10mm in diameter and 40-80 mm in length were used. Of them, eight stents were deployed across the elbow crease. Access patency was determined by clinical follow-up and the overall rates were calculated by Kaplan-Meier survival analysis. RESULTS: No procedure-related complications (stent fracture or central migration) were encountered except for a delayed Wallstent shortening/migration at the venous anastomosis, which resulted in early access failure. The overall primary and secondary patency rates (+/- standard error) of all the vascular accesses in our 23 patients at 3, 6, 12 and 24 months were 69% +/- 9 and 88% +/- 6, 41% +/- 10 and 88% +/- 6, 30% +/- 10 and 77% +/- 10, and 12% +/- 8 and 61% +/- 13, respectively. For the forearm and upper-arm grafts, the primary and secondary patency rates were 51% +/- 16 and 86% +/- 13 vs 45% +/- 15 and 73%+/-13 at 6 months, and 25% +/- 15 and 71% +/- 17 vs 23% +/- 17 and 73% +/- 13 at 12 months (p = .346 and .224), respectively. CONCLUSION: Metallic stent placement is a safe and effective means for treating peripheral venous lesions in dialysis graft patients after insufficient balloon dilation. No statistically difference in the patency rates between the forearm and upper-arm patient groups was seen.
Vascular Patency
;
Treatment Failure
;
Stents
;
Renal Dialysis
;
Polytetrafluoroethylene
;
Middle Aged
;
Metals
;
Male
;
Humans
;
Graft Occlusion, Vascular/*therapy
;
Forearm
;
Female
;
*Arteriovenous Shunt, Surgical
;
*Angioplasty, Balloon
;
Aged, 80 and over
;
Aged
7.Molecular Identification of Diphyllobothrium latum from a Pediatric Case in Taiwan.
Yu Chin AN ; Chia Cheng SUNG ; Chih Chien WANG ; Hsin Chung LIN ; Kuang Yao CHEN ; Fu Man KU ; Ruei Min CHEN ; Mei Li CHEN ; Kuo Yang HUANG
The Korean Journal of Parasitology 2017;55(4):425-428
Human diphyllobothriasis is a parasitic disease caused by ingestion of larvae (plerocercoids) in raw or undercooked fish and commonly found in temperate areas. Rare cases were reported in tropical or subtropical areas especially in children. The first documented case of pediatric diphyllobothriasis in Taiwan had been reported 11 years ago. Here, we report another 8-year-old girl case who presented with a live noodle-like worm hanging down from her anus, with no other detectable symptoms. We pulled the worm out and found the strobila being 260 cm in length. Examination of gravid proglottids showed that they were wider than their lengths, containing an ovoid cirrus sac in the anterior side and the rosette-shaped uterus. Eggs extracted from the uterus were ovoid and operculated. Diphyllobothrium latum was confirmed by molecular analysis of the mitochondrial DNA cytochrome c oxidase subunit 1 (cox1) gene. The girl was treated with a single oral dose of praziquantel, and no eggs or proglottids were observed from her stool in the subsequent 3 months. The reemergence of human diphyllobothriasis in non-endemic countries is probably due to prevalent habit of eating imported raw fish from endemic areas. This pediatric case raised our concern that human diphyllobothriasis is likely underestimated because of unremarkable symptoms.
Anal Canal
;
Child
;
Diphyllobothriasis
;
Diphyllobothrium*
;
DNA, Mitochondrial
;
Eating
;
Eggs
;
Electron Transport Complex IV
;
Female
;
Humans
;
Larva
;
Ovum
;
Parasitic Diseases
;
Praziquantel
;
Taiwan*
;
Uterus
8.Telbivudine-Induced Myopathy: Clinical Features, Histopathological Characteristics, and Risk Factors
Min-Yu LAN ; Hui-Chen L LIN ; Tsung-Hui HU ; Shu-Fang Ch CHEN ; Chien-Hung CHEN ; Yung-Yee CHANG ; King-Wah CHIU ; Tsu-Kung LIN ; Shun-Sheng CHEN
Journal of Clinical Neurology 2023;19(1):52-59
Background:
and Purpose Oral nucleos(t)ide analogs (NAs) are the mainstay treatment for chronic hepatitis B (CHB). Myotoxicity is an important extrahepatic effect related to NA treatment. Telbivudine is the NA for CHB that is frequently associated with muscle-related side effects. The risk factors for telbivudine-induced myopathy (TIM) are not yet clear.
Methods:
This study characterized the clinical, magnetic resonance images (MRI), and pathological features of 12 TIM cases. A group of telbivudine-tolerant (TT) patients with CHB who received regular telbivudine treatment during the same period without the occurrence of myopathy was collected. Demographic and clinical factors were compared between the patients with TIM and the TT controls. Factors independently associated with TIM were identified using logistic regression analysis.
Results:
The patients with TIM (males/females: 7/5, mean age: 57 years) developed myopathy after using telbivudine for a median period of 19.5 months. Muscle histopathology revealed abnormal proliferation, subsarcolemmal or sarcoplasmic accumulations, and ultrastructural defects of mitochondria. When compared with TT cases, patients with TIM had a lower estimated glomerular filtration rate and were more frequently positive for hepatitis B e antigen (HBeAg).
Conclusions
Mitochondrial abnormalities are characteristic histopathological features, and impaired renal function and HBeAg positivity are risk factors for TIM. Telbivudine-induced mitochondrial dysfunction and immune activation related to mitochondrial damage and HBeAg serostatus changes may underlie TIM. Constant clinical surveillance of myopathy during telbivudine treatment is needed due to the significant latency of its development. Dose adjustment for impaired renal function does not eliminate the risk of TIM occurrence.
9.Knowledge, Attitude, and Practice Survey of Gastroparesis in Asia by Asian Neurogastroenterology and Motility Association
Tadayuki OSHIMA ; Kewin T H SIAH ; Yong Sung KIM ; Tanisa PATCHARATRAKUL ; Chien-Lin CHEN ; Sanjiv MAHADEVA ; Hyojin PARK ; Min-Hu CHEN ; Ching-Liang LU ; Xiaohua HOU ; Duc T QUACH ; Ari F SYAM ; M Masudur RAHMAN ; Yinglian XIAO ; Liu JINSONG ; Andrew S B CHUA ; Hiroto MIWA
Journal of Neurogastroenterology and Motility 2021;27(1):46-54
Background/Aims:
Gastroparesis is identified as a subject that is understudied in Asia. The scientific committee of the Asian Neurogastroenterology and Motility Association performed a Knowledge, Attitude, and Practices survey on gastroparesis among doctors in Asia.
Methods:
The questionnaire was created and developed through a literature review of current gastroparesis works of literature by the scientific committee of Asian Neurogastroenterology and Motility Association.
Results:
A total of 490 doctors from across Asia (including Bangladesh, China, Hong Kong, Indonesia, Japan, Malaysia, Myanmar, the Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam) participated in the survey. Gastroparesis is a significant gastrointestinal condition. However, a substantial proportion of respondents was unable to give the correct definition and accurate diagnostic test. The main reason for lack of interest in diagnosing gastroparesis was “the lack of reliable diagnostic tests” (46.8%) or “a lack of effective treatment” (41.5%). Only 41.7% of respondents had access to gastric emptying scintigraphy. Most doctors had never diagnosed gastroparesis at all (25.2%) or diagnosed fewer than 5 patients a year (52.1%).
Conclusions
Gastroparesis can be challenging to diagnose due to the lack of instrument, standardized method, and paucity of research data on normative value, risk factors, and treatment studies in Asian patients. Future strategies should concentrate on how to disseminate the latest knowledge of gastroparesis in Asia. In particular, there is an urgent need to estimate the magnitude of the problems in high risk and idiopathic patients as well as a standardized diagnostic procedure in Asia.
10.Primary Care Management of Chronic Constipation in Asia: The ANMA Chronic Constipation Tool.
Kok Ann GWEE ; Uday C GHOSHAL ; Sutep GONLACHANVIT ; Andrew Seng Boon CHUA ; Seung Jae MYUNG ; Shaman RAJINDRAJITH ; Tanisa PATCHARATRAKUL ; Myung Gyu CHOI ; Justin C Y WU ; Min Hu CHEN ; Xiao Rong GONG ; Ching Liang LU ; Chien Lin CHEN ; Nitesh PRATAP ; Philip ABRAHAM ; Xiao Hua HOU ; Meiyun KE ; Jane D RICAFORTE-CAMPOS ; Ari Fahrial SYAM ; Murdani ABDULLAH
Journal of Neurogastroenterology and Motility 2013;19(2):149-160
Chronic constipation (CC) may impact on quality of life. There is substantial patient dissatisfaction; possible reasons are failure to recognize underlying constipation, inappropriate dietary advice and inadequate treatment. The aim of these practical guidelines intended for primary care physicians, and which are based on Asian perspectives, is to provide an approach to CC that is relevant to the existing health-care infrastructure. Physicians should not rely on infrequent bowel movements to diagnose CC as many patients have one or more bowel movement a day. More commonly, patients present with hard stool, straining, incomplete feeling, bloating and other dyspeptic symptoms. Physicians should consider CC in these situations and when patients are found to use laxative containing supplements. In the absence of alarm features physicians may start with a 2-4 week therapeutic trial of available pharmacological agents including osmotic, stimulant and enterokinetic agents. Where safe to do so, physicians should consider regular (as opposed to on demand dosing), combination treatment and continuous treatment for at least 4 weeks. If patients do not achieve satisfactory response, they should be referred to tertiary centers for physiological evaluation of colonic transit and pelvic floor function. Surgical referral is a last resort, which should be considered only after a thorough physiological and psychological evaluation.
Asia
;
Asian Continental Ancestry Group
;
Colon
;
Constipation
;
Health Resorts
;
Humans
;
Pelvic Floor
;
Physicians, Primary Care
;
Primary Health Care
;
Quality of Life
;
Referral and Consultation
;
Sprains and Strains